Page 64 - Read Online

R, Hosking F, Robertson L, Xiao Y, Wiencke J, Wrensch M, Andersson Antigen-specific T-cell response from dendritic cell vaccination using
U, Melin BS, Bondy M. Polymorphisms of LIG4, BTBD2, HMGA2, cancer stem-likecell-associated antigens. Stem Cells 2009;27:1734-40.
and RTEL1 genes involved in the double-strand break repair pathway 17. Bonomi A, Lisini D, Navone SE, Frigerio S, Dossena M, Ciusani
predict glioblastoma survival. J Clin Oncol 2010;28:2467-74. E, Rampini P, Marfia G, Coccè V, Cavicchini L, Sisto F, Parati E,
2. Alexiou GA, Goussia A, Voulgaris S, Fotopoulos AD, Fotakopoulos Mantegazza R, Rimoldi M, Rizzetto M, Alessandri G, Pessina A. Human
G, Ntoulia A, Zikou A, Tsekeris P, Argyropoulou MI, Kyritsis AP. CD14+ cells loaded with Paclitaxel inhibit in vitro cell proliferation of
Prognosticsignificance of MRP5 immunohistochemical expression glioblastoma. Cytotherapy 2015;17:310-9.
in glioblastoma. Cancer Chemotherapy and Pharmacology 18. Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC,
2012;69:1387-91. Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, clinical results of a personalized immunotherapeutic vaccine against
Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly recurrent, incompletely resected treatment-resistant glioblastoma
M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, multiforme (GBM) tumors, based on combined allo- and auto-immune
Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn tumor reactivity. Vaccine 2015;33:2690-6.
A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz 19. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves
G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE,
Integrated genomicanalysis identifies clinically relevant subtypes Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger
of glioblastomacharacterized by abnormalities in PDGFRA, IDH1, AB, Sampson JH. A phase II, multicenter trial of rindopepimut (CDX-
EGFR, and NF1. Cancer Cell 2010;17:98-110. 110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol
4. Weathers SP, Gilbert MR. Current challenges in designing GBM trials 2015;17:854-61.
for immunotherapy. J Neurooncol 2015;123:331-7. 20. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH,
5. Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell
neoplastic and infectious disease: Coley’s legacy revisited. Cytokine DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh
Growth Factor Rev 2009;20:271-81. JJ, Bigner DD. Immunologic escape after prolonged progression-
6. Alexiou GA, Kallinteri A, Michos E, Zagorianakou P, Priavali free survival with epidermal growth factor receptor variant III peptide
E, Pachatouridis D, Levidiotou S, Voulgaris S. The influence of vaccination in patients with newly diagnosed glioblastoma. J Clin
postoperative infection in survival of patients with high-grade gliomas. Oncol 2010;28:4722-9.
Neuroimmunol Neuroinflammation 2015;2:18-20. 21. Lewandowska MA, Furtak J, Szylberg T, Roszkowski K, Windorbska
7. Alexiou GA, Vartholomatos E, Zagorianakou P, Voulgaris S. Prognostic W, Rytlewska J, Jóźwicki W. An analysis of the prognostic value of
significance of neutrophil-to-lymphocyte ratio in glioblastoma. IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Neuroimmunol Neuroinflammation 2014;1:131-4. Mol Diagn Ther 2014;18:45-53.
8. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune 22. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J,
resistance and sources of immunosuppression. Gene Ther Mol Biol Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach
2006;10:133-146. K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB,
9. Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P,
Kresak J, Sampson JH, Mitchell DA. Increased proportion of FoxP3+ von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1
regulatory T cells in tumor infiltrating lymphocytes is associated with induces antitumour immunity. Nature 2014;512:324-7.
tumor recurrence and reduced survival in patients with glioblastoma. 23. Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi
Cancer Immunol Immunother 2015;64:419-27. Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G.
10. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Effective immuno-targeting of the IDH1 mutation R132H in a murine
Giovannone AJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell model of intracranial glioma. Acta Neuropathol Commun 2015;3:4.
vaccination in glioblastoma patients induces systemic and intracranial 24. Alexiou GA, Vartholomatos G, Stefanaki K, Patereli A, Dova L,
T-cell responses modulated by the local central nervous system tumor Karamoutsios A, Lallas G, Sfakianos G, Moschovi M, Prodromou N.
microenvironment. Clin Cancer Res 2005;11:5515-25. Expression of heat shock proteins in medulloblastoma. J Neurosurg
11. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Pediatr 2013;12:452-7.
Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, 25. Nishikawa M, Takemoto S, Takakura Y. Heat shock protein derivatives
Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW. for delivery of antigens to antigen presenting cells. Int J Pharm
Postoperative adjuvant dendritic cell-based immunotherapy in 2008;354:23-7.
patients with relapsed glioblastoma multiforme. Clin Cancer Res 26. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N,
2008;14:3098-104. Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa
12. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson AT. Individual patient-specific immunity against high-grade glioma
R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of after vaccination with autologous tumor derived peptides bound to the
glioma-associated antigen peptide-loaded versus autologous tumor 96 KD chaperone protein. Clin Cancer Res 2013;19:205-14.
lysate-loaded dendritic cell vaccination in malignant glioma patients. 27. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski
J Immunother 2013;36:152-7. NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan
13. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96
Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth vaccination for recurrent glioblastoma: a phase II, single-arm trial.
E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Neuro Oncol 2014;16:274-9.
Langmoen IA. Therapeutic vaccination against autologous cancer 28. Wu ZB, Cai L, Qiu C, Zhang AL, Lin SJ, Yao Y, Xu J, Zhou LF. CTL
stem cells with mRNA-transfected dendritic cells in patients with responses to HSP47 associated with the prolonged survival of patients
glioblastoma. Cancer Immunol Immunother 2013;62:1499-509. with glioblastomas. Neurology 2014;82:1261-5.
14. Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova 29. Yan Y, Fang M, Xuan W, Wu X, Meng X, Wang L, Yu Y. The
IV, Pytel P, Han Y, Tobias A, Zhang L, Qiao J, Lesniak MS. Dendritic Therapeutic Potency of HSP65-GTL in GL261 Glioma-bearing Mice.
Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid J Immunother 2015;38:341-9.
Cells Offer a Superior Survival Advantage in Malignant Glioma. J 30. Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hídvégi EJ,
Immunol 2015;195:367-76. Hamada H, Sáfrány G. Detailed characterization of the mouse glioma
15. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair 261 tumor model for experimental glioblastoma therapy. Cancer Sci
SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, 2006;97:546-53.
Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, 31. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R.
Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 Expression of VEGF and its receptors in different brain tumors. Neurol
improve dendritic cell vaccines in mice and glioblastoma patients. Res 2005;27:371-7.
Nature 2015;519:366-9. 32. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized
16. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS. anti-VEGF monoclonal antibody for cancer therapy. Biochem

Neuroimmunol Neuroinflammation | Volume 3 | March 14, 2016 55